To amend the Harmonized Tariff Schedule for the United States to establish a new subheading in chapter 39 for silicone prosthetics for women who are breast cancer survivors and a new subheading in chapter 90 for mastectomy bras.
Summary
HR10147 proposes technical amendments to the Harmonized Tariff Schedule to create separate subheadings for silicone prosthetics for breast cancer survivors and mastectomy bras. The bill is in early stage, referred to the House Ways and Means Committee, with no funding or direct market impact. No publicly traded companies have a clear causal link to this narrow tariff classification change.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10147 is a procedural tariff classification bill with no funding or direct market impact.
- 2.No publicly traded company has a clear causal chain to this bill; the affected market is niche and largely private.
- 3.The bill is in early stage with low legislative momentum; passage is uncertain and would not create material revenue shifts.
Market Implications
The bill's impact on public markets is negligible. Investors should not expect any measurable movement in healthcare or medical device stocks from this tariff classification change. The affected product categories (silicone prosthetics, mastectomy bras) are not dominated by any single publicly traded company, and the bill does not alter reimbursement, procurement, or regulatory pathways.
Full Analysis
HR10147, introduced by Rep. Carol Miller (R-WV-1) with one cosponsor (Rep. Terri Sewell, D-AL-7), would amend the Harmonized Tariff Schedule to establish new subheadings for silicone prosthetics for breast cancer survivors and mastectomy bras. The bill is at the earliest legislative stage—referred to the House Committee on Ways and Means on August 24, 2026. It does not authorize or appropriate any funding; it is a customs classification change that could affect duty rates or import procedures for these specific products. The mechanism is purely administrative: creating distinct tariff codes to potentially lower or clarify duties. There is no direct revenue impact on any publicly traded company because the affected products are typically manufactured by private or niche companies (e.g., Amoena, TruLife) or are small segments within larger medical device firms. The bill has no convergence with other signals in the provided data. Legislative momentum is low: a single sponsor from the minority party, one cosponsor, and only three procedural actions. The path to law requires committee markup, House passage, Senate companion bill, and presidential action—unlikely in the current session given the narrow scope and early stage.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
ALABAMA MEDICAID AGENCY: $6.3B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
DISTRICT OF COLUMBIA, GOVERNMENT OF: $2.9B Department of Health and Human Services Grant
HEALTH & HUMAN SVC COMMN TX: $1.3B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →